Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Personalis Inc is a diagnostics & research business based in the US. Personalis shares (PSNL) are listed on the NASDAQ and all prices are listed in US Dollars. Personalis employs 325 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Active traders
| Latest market close | $3.73 |
|---|---|
| 52-week range | $3.13 - $25.20 |
| 50-day moving average | $4.41 |
| 200-day moving average | $11.25 |
| Wall St. target price | $19.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-1.82 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $3.73 from 2022-07-05
| 1 week (2022-06-30) | 8.12% |
|---|---|
| 1 month (2022-06-07) | -2.86% |
| 3 months (2022-04-05) | -55.11% |
| 6 months (2022-01-07) | -71.13% |
| 1 year (2021-07-07) | -84.16% |
|---|---|
| 2 years (2020-07-07) | -73.81% |
| 3 years (2019-07-05) | 22.3 |
| 5 years (2017-07-03) | N/A |
| Revenue TTM | $79.8 million |
|---|---|
| Gross profit TTM | $31.7 million |
| Return on assets TTM | -13.07% |
| Return on equity TTM | -25.52% |
| Profit margin | -101.49% |
| Book value | $6.34 |
| Market capitalisation | $154.5 million |
TTM: trailing 12 months
We're not expecting Personalis to pay a dividend over the next 12 months.
Over the last 12 months, Personalis's shares have ranged in value from as little as $3.13 up to $25.195. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Personalis's is 1.7391. This would suggest that Personalis's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test enabling composite biomarkers for cancer treatment; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves biopharmaceutical customers, universities, non-profits, and government entities. The company has partnership with Mayo Clinic; MapKure, LLC; SpringWorks Therapeutics, Inc.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.